Plasma CCSP‐2 showed comparable sensitivity for detection of advanced adenomas and of CRCs, providing the first proof of the utility of blood biomarker detection for curable CRC precursor lesions. This evidence concerns the gene SCGB1A1 and colorectal carcinoma.